These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32326341)

  • 1. Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer.
    Regel I; Mayerle J; Mahajan UM
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32326341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unsupervised subtyping and methylation landscape of pancreatic ductal adenocarcinoma.
    Roy S; Singh AP; Gupta D
    Heliyon; 2021 Jan; 7(1):e06000. PubMed ID: 33521362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians.
    Giannis D; Moris D; Barbas AS
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33802340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer.
    Khomiak A; Brunner M; Kordes M; Lindblad S; Miksch RC; Öhlund D; Regel I
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33147766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
    Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
    JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the management of pancreatic cancer: surgery is not enough.
    Ansari D; Gustafsson A; Andersson R
    World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical models derived from endoscopic ultrasound-guided tissue acquisition for individualized treatment of pancreatic ductal adenocarcinoma.
    Tong T; Zhang C; Li J; Deng M; Wang X
    Front Med (Lausanne); 2022; 9():934974. PubMed ID: 36687406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and Emerging Therapies in Metastatic Pancreatic Cancer.
    Manji GA; Olive KP; Saenger YM; Oberstein P
    Clin Cancer Res; 2017 Apr; 23(7):1670-1678. PubMed ID: 28373365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer?
    Sereti E; Karagianellou T; Kotsoni I; Magouliotis D; Kamposioras K; Ulukaya E; Sakellaridis N; Zacharoulis D; Dimas K
    J Proteomics; 2018 Sep; 188():107-118. PubMed ID: 29398619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic Cancer Immuno-oncology in the Era of Precision Medicine.
    Hegde S
    Indian J Surg Oncol; 2021 Apr; 12(Suppl 1):118-127. PubMed ID: 33994737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrin-based therapy of pancreatic adenocarcinoma: current status and future perspectives.
    Oron Y
    Minerva Gastroenterol Dietol; 2015 Jun; 61(2):71-86. PubMed ID: 25610998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer?
    Kokkinos J; Jensen A; Sharbeen G; McCarroll JA; Goldstein D; Haghighi KS; Phillips PA
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34067833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pancreatic adenocarcinoma to predict the pattern of recurrence of the disease.
    Popp FC; Popp MC; Zhao Y; Betzler C; Kropf S; Garlipp B; Benckert C; Kalinski T; Lippert H; Bruns CJ
    BMC Cancer; 2017 Mar; 17(1):229. PubMed ID: 28356064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective.
    Perales-Patón J; Piñeiro-Yañez E; Tejero H; López-Casas PP; Hidalgo M; Gómez-López G; Al-Shahrour F
    Public Health Genomics; 2017; 20(2):81-91. PubMed ID: 28858862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
    Zhao L; Zhao H; Yan H
    BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response assessment in pancreatic ductal adenocarcinoma: role of imaging.
    Baliyan V; Kordbacheh H; Parakh A; Kambadakone A
    Abdom Radiol (NY); 2018 Feb; 43(2):435-444. PubMed ID: 29243123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier.
    Bhasin MK; Ndebele K; Bucur O; Yee EU; Otu HH; Plati J; Bullock A; Gu X; Castan E; Zhang P; Najarian R; Muraru MS; Miksad R; Khosravi-Far R; Libermann TA
    Oncotarget; 2016 Apr; 7(17):23263-81. PubMed ID: 26993610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers in pancreatic ductal adenocarcinoma.
    Gallego J; López C; Pazo-Cid R; López-Ríos F; Carrato A
    Clin Transl Oncol; 2017 Dec; 19(12):1430-1437. PubMed ID: 28616721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. State of the art and future directions of pancreatic ductal adenocarcinoma therapy.
    Neuzillet C; Tijeras-Raballand A; Bourget P; Cros J; Couvelard A; Sauvanet A; Vullierme MP; Tournigand C; Hammel P
    Pharmacol Ther; 2015 Nov; 155():80-104. PubMed ID: 26299994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.